New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 21, 2014
10:49 EDTGOOG, NSR, CMG, SRPT, INFYOptions with decreasing implied volatility: SRPT NSR INFY CMG GOOG
News For SRPT;NSR;INFY;CMG;GOOG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
August 20, 2015
05:56 EDTGOOGGoogle Express to shut down two California delivery hubs, Re/code says
Subscribe for More Information
August 19, 2015
13:13 EDTGOOGGoogle says to open YouTube production space in Mumbai 'soon'
Subscribe for More Information
10:42 EDTGOOGAnalyst increases Google price target by $265, upgrades to buy
Research firm Atlantic Equities upgraded Google (GOOG, GOOGL) to Overweight from Market Weight, saying that it is more upbeat on the company's search business, while YouTube is becoming a major growth driver. Additionally, the search giant's margins look poised to improve, the firm stated. Overweight is Atlantic's equivalent of a buy rating. WHAT'S NEW: Google's second quarter results showed that its search business is weathering the transition to mobile better than expected, Atlantic Equities analyst James Cordwell stated in a note to investors today. Meanwhile, YouTube's revenue, despite growing very quickly, can rise even further since it still accounts for just roughly 5% of global TV viewing outside of China, according to Cordwell. Additionally, the movement of ad dollars from conventional TV to online TV looks set to accelerate, the analyst believes. Furthermore, Google is undertaking initiatives that should cause the amount of money it obtains from each mobile click to rise, the analyst believes. Commenting on the outlook for Google's margins, Cordwell believes that they should be boosted by the cost cuts being undertaken by the company's new CFO. The analyst raised his price target on the company's Class A shares to $825 from $560. PRICE ACTION: In mid-morning trading, Google's common stock rose $2.60 to $658.73 and its Class A shares rose $2.70 to $691.43.
10:00 EDTCMGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Biocept (BIOC) initiated with a Buy at H.C. Wainwright... C.H. Robinson (CHRW) initiated with a Buy at Evercore ISI... Chipotle (CMG) initiated with a Hold at Maxim... Con-way (CNW) initiated with a Buy at Evercore ISI... Dermira (DERM) initiated with an Outperform at Cowen... Expeditors (EXPD) initiated with a Hold at Evercore ISI... Fleetmatics (FLTX) initiated with an In-Line at Imperial Capital... Frontier Communications (FTR) initiated with an Overweight at Stephens... Gevo (GEVO) initiated with a Buy at Rodman & Renshaw... International Game (IGT) initiated with a Sell at Goldman... Knight Transportation (KNX) initiated with a Buy at Evercore ISI... Logitech (LOGI) initiated with a Buy at Rosenblatt... Navistar (NAV) initiated with a Neutral at Macquarie... Panera Bread (PNRA) initiated with a Hold at Maxim... Scientific Games (SGMS) initiated with a Sell at Goldman... Swift Transport (SWFT) initiated with a Hold at Evercore ISI... Tribune Media (TRCO) initiated with an Equal Weight at Morgan Stanley... WEX Inc. (WEX) initiated with an Equal Weight at Barclays... Zoe's Kitchen (ZOES) initiated with a Buy at Maxim.
10:00 EDTGOOGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:17 EDTSRPT'Female Viagra' approval seen as positive for Sarepta, BioMarin
The FDA's approval of the world's first drug designed to boost a woman's sexual desire is seen as boding well for companies awaiting critical decisions by the agency. FEMALE VIAGRA: The Food and Drug Administration yesterday approved flibanserin to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. The drug, which will be sold under the name "Addyi" and is commonly referred to as the "female Viagra," is the first FDA-approved treatment for sexual desire disorders in men or women, the agency prominently stated in its press release. HSDD is characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance, the FDA explained. Addyi was approved with a risk evaluation and mitigation strategy as well as a Boxed Warning given the risk of severe hypotension and syncope in patients who drink alcohol during treatment. The drug is made by privately held Sprout Pharmaceuticals. ANALYST REACTION: Addyi's approval is "another sign of flexibility" by the FDA, especially for first-in-class therapies, Roth Capital analyst Debjit Chattopadhyay writes this morning in a note to investors. This bodes well for the approval of eteplirsen, drisapersen and Translarna, the analyst contends. Eteplirsen, designed by Sarepta Therapeutics (SRPT), and drisapersen, designed by BioMarin (BMRN), are experimental drugs being developed to treat Duchenne muscular dystrophy. Translarna, designed by PTC Therapeutics (PTCT), is already being sold in Europe as a treatment for DMD and is awaiting approval from the FDA. Duchenne muscular dystrophy is a form of muscular dystrophy affecting around 1 in 3,600 boys, which results in muscle degeneration and premature death. SAVING LIVES: While female sexual dysfunction is a clinical problem, eteplirsen is designed to save lives, Chattopadhyay points out. He has a Buy rating on Sarepta and noted his price target of $45 assumes accelerated approval for eteplirsen in the first quarter of 2016. Shares of the Massachusetts-based biopharmaceutical company closed yesterday at $35.69.
08:29 EDTSRPTFlibanserin approval bodes well for Sarepta, others, says Roth Capital
Subscribe for More Information
06:53 EDTGOOGDeutsche Telekom exec calls for internet firms to subsidize online ads, FT says
Deutsche Telekom (DTEGY) senior vice president of technology strategy, governance, and programs Tomasz Gerszberg has called for internet companies such as Google (GOOG) and Facebook (FB) to subsidize users' mobile subscriptions due to the new way advertising takes over data allowances, the Financial Times reports, citing an article Gerszberg wrote on LinkedIn. The Deutsche Telekom executive said that consumers need to be protected from rising data charges related to "annoying" online ads, the report says. Reference Link
06:25 EDTGOOGGoogle upgraded to Overweight from Neutral at Atlantic Equities
Atlantic Equities analyst James Cordwell upgraded Google (GOOG, GOOGL) to Overweight and raised his price target for shares to $825 from $560. The search giant closed yesterday down $5.38 to $688.73. Google's YouTube unit "continues to grow very rapidly," while the revenue growth of Google Websites suggests the company is navigating the mobile transition on search better than expected, Cordwell tells investors in a research note. Further, a greater focus on costs by the new CFO is driving improved profitability, a trend that should continue, the analyst argues. Cordwell expects continued outperformance of Google shares.
05:56 EDTGOOGStocks with implied volatility below IV index mean; GMCR GOOG
Subscribe for More Information
August 18, 2015
18:52 EDTCMGChipotle initiated with a Hold at Maxim
Subscribe for More Information
15:25 EDTGOOGGoogle introduces OnHub router
In a post to its official blog, Google said "While we count on Wi-Fi more than ever to be entertained, productive, and stay connected, we're streaming and sharing in new ways our old routers were never built to handle. So today, with our partner TP-LINK, we're launching OnHub, a different kind of router for a new way to Wi-Fi. Instead of headaches and spotty connections, OnHub gives you Wi-Fi that's fast, secure, and easy to use." Reference Link
06:16 EDTCMGFast food chains making new push with more fresh ingredients, WSJ says
Subscribe for More Information
06:02 EDTGOOGStocks with implied volatility below IV index mean; GMCR GOOG
Subscribe for More Information
August 17, 2015
19:54 EDTGOOGComcast online video platform to give creators 70% share of ad revenue, WSJ says
Subscribe for More Information
19:00 EDTGOOGGoogle targets 2016 U.S. launch for modular smartphone project
Subscribe for More Information
16:14 EDTGOOGParkway Properties signs deal to bring Google Fiber to certain properties
Subscribe for More Information
12:42 EDTGOOGGoogle says testing Project Sunroof
Subscribe for More Information
06:22 EDTSRPTPiper's Tenthoff sees select biotech names outperforming in second half
Piper Jaffray analyst Edward Tenthoff expects drug launches, clinical data read-outs and potential partnerships to drive outperformance for select biotech names in the second half of 2015. Despite some recent profit-taking, 2015 has been another strong year for biotech stocks, Tenthoff tells investors in a research note. Names with important second half of the year catalysts include Vertex (VRTX), Regeneron (REGN), Seattle Genetics (SGEN), Exelixis (EXEL), Sarepta (SRPT), Novavax (NVAX), Arrowhead (ARWR), Array BioPharma (ARRY), Alnylam (ALNY), Genocea (GNCA), CymaBay (CBAY), Idera Pharmaceuticals (IDRA), Vitae Pharmaceuticals (VTAE).
06:03 EDTGOOGStocks with implied volatility below IV index mean; GMCR GOOG
Stocks with implied volatility below IV index mean; Keurig Green Mountain (GMCR) 38, Google (GOOG) 23 according to iVolatility.
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use